Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
SGN-B7H4V Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562646
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
靶标信息
SGN-B7H4V is an investigational vedotin antibody-drug conjugate (ADC) targeting B7-H4 an immune checkpoint ligand overexpressed in various cancer types. The ADC comprises a B7-H4-directed human monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE) through a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. This innovative vedotin linker-payload system has been validated in clinical settings showcasing potential effectiveness in enhancing antitumor activity. SGN-B7H4V is explored in a first-in-human phase 1 clinical trial assessing its safety tolerability pharmacokinetics and antitumor efficacy in patients with advanced solid tumors. This biosimilar is formulated for storage at -20C to -80C to maintain stability ensuring its viability for research and experimental applications. Its development underscores the importance of targeting immune checkpoints that contribute to cancer progression for therapeutic advancements.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
